In cancer cells, the cGAS-STING signaling axis is linked with remodeling of the immunosuppressive TME [15,16], and, via the resulting type 1 IFNs, upregulation of suppressed major histocompatibility complex (MHC) class I expression necessary for CTL recognition and targeting [17]. The gene discussed is STING1; the disease is cancer.